10,244 followers
The results of the Phase I safety/tolerability, pharmacokinetics & pharmacodynamics clinical trial of KM-819 (a FAS-associated factor 1 inhibitor) in healthy volunteers have been published. This drug is being developed for #Parkinsons https://t.co/zEG7